S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Kissei Pharmaceutical Stock Price, News & Analysis (OTCMKTS:KSPHF)

$18.81
0.00 (0.00%)
(As of 05/24/2023)
Compare
Today's Range
$18.81
$18.81
50-Day Range
$18.81
$18.81
52-Week Range
$17.71
$19.90
Volume
1 shs
Average Volume
983 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is headquartered in Matsumoto, Japan.

KSPHF Stock Price History

KSPHF Stock News Headlines

Kissei Pharmaceutical Co Ltd
Kissei Pharmaceutical Co Ltd (4547)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Kissei Pharmaceutical Co. Ltd.
Kissei Pharmaceutical Co., Ltd. (KSPHF)
Kissei Pharmaceutical Co. Ltd (KSPHF)
What Wall Street expects from Kissei Pharmaceutical's earnings
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Kissei Pharmaceutical earnings: here's what Wall Street expects
See More Headlines
Receive KSPHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kissei Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:KSPHF
CIK
N/A
Fax
N/A
Employees
1,359
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Yasuo Takehana (Age 63)
    President, CEO & Director
  • Mr. Takahide Kitahara (Age 61)
    GM of Financial Management Department, MD & Director
  • Mr. Yoshio Furihata (Age 61)
    Senior Advisor & Director
  • Mr. Keiji Fukushima (Age 67)
    Executive VP & Director
  • Mr. Tetsu Takayama (Age 62)
    Senior MD & Director
  • Hiroshi Noake (Age 59)
    GM of Pharmaceutical Sales Headquarters & Director
  • Keiji Miyazawa (Age 56)
    GM of Research Division & Director














KSPHF Stock Analysis - Frequently Asked Questions

How have KSPHF shares performed in 2023?

Kissei Pharmaceutical's stock was trading at $18.3950 at the beginning of 2023. Since then, KSPHF shares have increased by 2.3% and is now trading at $18.81.
View the best growth stocks for 2023 here
.

Are investors shorting Kissei Pharmaceutical?

Kissei Pharmaceutical saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 33,000 shares, an increase of 114.3% from the October 31st total of 15,400 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View Kissei Pharmaceutical's Short Interest
.

How do I buy shares of Kissei Pharmaceutical?

Shares of KSPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:KSPHF) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -